Effects of low doses of esmolol on cardiac and vascular function in experimental septic shock by unknown
RESEARCH Open Access
Effects of low doses of esmolol on cardiac
and vascular function in experimental
septic shock
Chaojie Wei1,2, Huguette Louis2,3, Margaux Schmitt1, Eliane Albuisson2,4, Sophie Orlowski1,2, Bruno Levy1,2,5*
and Antoine Kimmoun1,2,5
Abstract
Background: Administration of a selective β1-blocker, such as esmolol, in human septic shock has demonstrated
cardiovascular protective effects related to heart rate reduction. Certain experimental data also indicate that esmolol
exerts systemic anti-inflammatory and beneficial effects on vascular tone. Thus, the present study aimed to determine
whether a non-chronotropic dose of esmolol maintains its protective cardiovascular and anti-inflammatory effects in
experimental septic shock.
Methods: Four hours after cecal ligation and puncture (CLP), Wistar male rats were randomly allocated to the
following groups (n = 8): CLP, CLP + E-1 (esmolol: 1 mg.kg−1.h−1), CLP + E-5 (esmolol: 5 mg.kg−1.h−1), CLP + E-18
(esmolol: 18 mg.kg−1.h−1). An additional eight rats underwent sham operation. All rats received a continuous
infusion of saline, analgesic and antibiotics 4 hours after the surgery. Assessment at 18 hours included in vivo
cardiac function assessed by echocardiography and ex vivo vasoreactivity assessed by myography. Circulating
cytokine levels (IL-6 and IL-10) were measured by ELISA. Cardiac and vascular protein expressions of p-NF-κB,
IκBα, iNOS, p-AKT/AKT and p-eNOS/eNOS were assessed by western blotting.
Results: CLP induced tachycardia, hypotension, cardiac output reduction, hyperlactatemia and vascular hypo-
responsiveness to vasopressors. Compared to CLP animals, heart rate was unchanged in CLP + E-1 and CLP +
E-5 but was reduced in CLP + E-18. Stroke volume, cardiac output, mean arterial pressure and lactatemia were
improved in CLP + E-1 and CLP + E-5, while vascular responsiveness to phenylephrine was only improved in
CLP + E-5 and CLP + E-18. Plasma IL-6 levels were decreased in all esmolol groups. p-NF-κB was decreased in
both cardiac and vascular tissues in CLP + E-5 and CLP + E-18.
Conclusion: In experimental septic shock, low doses of esmolol still improved cardiac function and
vasoreactivity. These benefits appear to be associated with a modulation of inflammatory pathways.
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Background
Septic shock is associated with dysfunction of the auto-
nomic system triggered by a massive release of pro-
inflammatory cytokines [1–4]. Loss of cardiovascular
variability, inappropriate tachycardia and excessive cat-
echolamine release leading to the onset of multiple
organ failure and death are the main symptoms of this
autonomic dysfunction. Selective β1-blockade is one
approach currently under assessment to downregulate
this dysfunction [5–7].
In animals with experimental septic shock, a selective
β1-blocker such as esmolol efficiently improves both
cardiac and vascular functions [8–13]. Most of these
hemodynamic changes could be related to the pleio-
tropic effects of esmolol, including reduction in heart
rate, but also to downregulation of inflammatory path-
ways. Nevertheless, reduction in heart rate alone does
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not explain all of the beneficial effects observed with
esmolol. Indeed, we previously demonstrated in an
experimental model of septic shock that isolated reduc-
tion in heart rate by ivabradine (an If channel inhibitor)
does not induce any change in inflammatory status [14].
In humans, Morelli, et al. and others have demon-
strated in their respective studies that esmolol is efficient
in decreasing heart rate in patients with septic shock
[10, 15, 16]. Morelli et al. also observed a reduction in
norepinephrine requirement in treated patients [10, 16].
In these studies, the dose of esmolol was chosen to
achieve a reduction in heart rate of approximately 20%.
This dose, however, was systematically associated with an
initial decrease in cardiac output, thus rendering its pre-
scription delicate in hemodynamically precarious patients
with sepsis. On the other hand, Ibrahim-Zada et al. dem-
onstrated that low-dose esmolol (6.7 μg.kg−1.min−1),
which does not reduce heart rate, increases the survival
rate in an endotoxic mouse model of sepsis. The authors
hypothesize that the survival benefits are related to the
modulation of inflammatory genes [17].
Using an experimental model of septic shock, the pur-
pose of the present study was to determine whether low
doses of esmolol, which do not reduce heart rate, are
associated with beneficial effects on: (1) in vivo left ven-
tricular systolic function assessed by echocardiography,
(2) ex vivo vascular responsiveness to phenylephrine
(Phe) and vascular relaxation to acetylcholine (Ach) of
the thoracic aorta and mesenteric artery and (3) sys-
temic, cardiac and vascular inflammatory pathways.
Method
Animals
Male Wistar rats (Janvier, France) weighing 300–400 g
were used after an acclimation period of at least one
week prior to experimentation. All animal experimenta-
tion protocols were approved by the French Animal
Care Committee in keeping with European regulations.
The study was conducted in a university research
laboratory.
Shock model: cecal ligation and puncture (CLP)
This model has previously been described in detail [14].
Additional information on this model is provided in
Additional file 1.
Fluid resuscitation management
Four hours after CLP induction, all rats received a con-
tinuous infusion of saline, analgesic (nalbuphin
0.2 mg.kg−1.h−1) and anti-infective therapy (imipenem
and cilastatin sodium 10 mg.kg−1). The total infusion
rate was fixed at 10 ml.kg−1.h−1.
Esmolol dosage
The aim of this pre-experimental series was to iden-
tify a dose of esmolol that does not reduce heart rate
18 hours after the onset of CLP. Given that esmolol
at 10 mg.kg−1.h−1 still induced reduction in heart rate
at 18 hours after onset of CLP in the study of Suzuki
et al., the first tested dose was 5 mg.kg−1.h−1 (n = 4),
initiated 4 hours after surgery [8]. A second group
also received esmolol at 18 mg.kg−1.h−1 (n = 4). Heart
rate in these two groups was compared with heart
rate in a CLP group (n = 8) extracted from our previ-
ous study using the exact same protocol [14]. Heart
rate was calculated in each group by echocardiog-
raphy at 18 hours after the onset of CLP. Infusion of
esmolol 5 mg.kg−1.h−1 did not reduce heart rate compared
to heart rate in the CLP group (Additional file 2: Figure S1).
In view of the hypothesis of Ibrahim-Zada et al.
suggesting that very low doses of selective β1-
adrenoreceptor antagonist still present immunomodu-
latory effects in endotoxic shock, an esmolol dose of
1 mg.kg−1.h−1 was also tested [17].
Experimental design
Four hours after CLP, Wistar rats were randomly allo-
cated to one of the following groups: CLP (n = 8), CLP +
E-1 (esmolol 1 mg.kg−1.h−1 initiated 4 hours after sur-
gery for a period of 14 hours (n = 8)), CLP + E-5 (esmo-
lol 5 mg.kg−1.h−1 initiated 4 hours after surgery for a
period of 14 hours (n = 8)), or CLP + E-18 (esmolol
18 mg.kg−1.h−1 initiated 4 hours after surgery for a
period of 14 hours (n = 8)). Rats that underwent sham
operation were allocated to the sham group. Assess-
ments were performed 18 hours after surgery.
Echocardiography procedure
Hemodynamic investigation was initiated 18 hours after
surgery. This procedure has previously been detailed and
is provided in Additional file 1 [14].
Vascular reactivity procedure
After the animals were killed by exsanguination under
isoflurane, the thoracic aorta and mesentery were
removed and their vasoreactivity was studied. The pro-
cedure is detailed in Additional file 1.
Cytokine analyses
Plasma IL-6 and IL-10 were measured in duplicate with
the use of rat IL-6 and IL-10 ELISA kits (Quantikine
ELISA; R&D Systems Europe, Abingdon, UK) according
to the manufacturer’s instructions. Results are expressed
as picograms of the measured cytokine per milliliter of
plasma.
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Western blotting
The thoracic aorta and heart were homogenized and lysed,
and proteins (25 μg) were separated on 10% SDS-PAGE.
Blots were probed with the following antibodies:
phosphorylated-AKT (p-AKT) (rabbit anti-rat AKT, phos-
phorylated (Ser473)), AKT (AKT-pan (C67E7)), phosphor-
ylated endothelial nitric oxide synthase (p-eNOS) (rabbit
anti-rat eNOS, phosphorylated (Ser1177)), endothelial
nitric oxide synthase (eNOS) (rabbit anti-rat eNOS), phos-
phorylated NF-κB (Phospho-NF-κB p65 (Ser536) (93H1))
and IκBα ((44D4)), all from Cell Signaling Technology,
Saint Quentin Yvelines, France; anti-iNOS (Abcam, Paris,
France) and β-actin (13E5) (Cell Signaling Technology,
Saint Quentin Yvelines, France). Proteins were transferred
onto nitrocellulose membranes after which bound anti-
bodies were detected with a secondary peroxidase-
conjugated anti-rabbit IgG (Promega, Madison, WI, USA).
The blots were visualized using an enhanced chemilumin-
escence system (ECL Plus; Amersham, GE Healthcare
Europe, Velizy-Villacoublay, France).
RNA extraction and quantitative reverse transcriptase-
polymerase chain reaction of α1-adrenoreceptor,
β1-adrenoreceptor and β2-adrenoreceptor
Total RNA extraction was carried out with the RNA
Plus mini Kit (Qiagen, Courtaboeuf Cedex, France)
according to the manufacturer’s instructions. The pro-
cedure is provided in Additional file 1.
Statistical analysis
Results are expressed as median with minimum and
maximum values in the main text, as median with mini-
mum, maximum values and interquartile range (median
(min-max); (interquartile range IQR)) in the tables, and
as median with upper edges of error bars representing
the 75th percentile in the figures. Because of the small
sample size, all analyses were performed with nonpara-
metric methods. The Mann–Whitney U test was used to
determine whether the two independent samples in the
sham and CLP groups stemmed from a population with
a common median. The Kruskal-Wallis test was used to
determine whether the four independent samples in the
CLP, CLP + E-1, CLP + E-5 and CLP + E-18 groups
stemmed from a population with a common median.
When the Kruskal-Wallis test was significant at the 5%
level, post hoc comparisons were performed between the
CLP, CLP + E-1, CLP + E-5 and CLP + E-18 groups, using
Dunn’s multiple comparisons procedure. The PRISM
nonlinear curve-fitting tool (GraphPad Software, San
Diego, CA, USA) was used to depict the results of vasor-
eactivity testing. The two-tailed statistical significance
level was set at 5%. Statistical analyses were performed
using IBM-SPSS Statistics 22.0 (IBM corp.) and Graph-
Pad Software 6.0, (San Diego, CA, USA).
Results
Model characterization
Compared to animals in the sham group, CLP
induced arterial hypotension (sham 103 mmHg (94–
114); CLP 74 mmHg (59–83)) and hyperlactatemia
(sham 1.1 mmol.l−1 (0.9–1.9); CLP 2.5 mmol.l−1 (1.6–
3.5)). Cardiac output was decreased with CLP com-
pared to animals in the sham group (sham:
111 ml.min−1 (94–122); CLP: 43 ml.min−1 (25–58))
(Table 1).
In the isolated aorta and small mesenteric arteries
(SMA), compared to animals in the sham group, CLP
conversely blunted Phe-induced contraction (Fig. 1a, c).
Compared to animals in the sham group, vascular
responses to Ach were decreased with CLP in the
isolated aorta and SMA (Fig. 1b, d).
Hemodynamic effects after different doses of esmolol in
animals that underwent CLP
Addition of esmolol at 18 mg.kg−1.h−1 induced a de-
crease in heart rate in the CLP group (CLP 419 bpm
Table 1 Comparison of hemodynamic characteristics 18 hours after cecal ligation and puncture using echocardiography
Variables Sham IQR CLP IQR P value
n = 8 n = 8
Median Min-Max Median Min-Max
Heart rate (min−1) 372 361–396 368–373 419 349–472 381–452 0.015
Mean arterial pressure (mmHg) 103 94–114 100–113 74 59–83 67–81 <0.001
LVIDs (mm) 3.85 3.60–4.63 3.78–4.22 2.76 0.99–4.07 2.26–3.46 0.003
LVIDd (mm) 7.66 7.33–8.51 7.41–8.23 5.41 2.70–7.38 4.99–6.24 <0.001
Stroke volume (μl) 302 256–327 277–304 92 71–144 73–120 <0.001
Cardiac output (ml.min−1) 111 94–122 107–113 43 25–58 29–49 <0.001
Ejection fraction (%) 85 82–88 83–87 88 51–94 84–92 0.083
Lactatemia (mmol.l−1) 1.1 0.9–1.9 1.0–1.5 2.5 1.6–3.5 2.1–2.8 <0.001
Data were analyzed using the Mann–Whitney U test. CLP cecal ligature and puncture, LVIDs left ventricular internal diameter end systole, LVIDd left ventricular
internal diameter end diastole
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(349–472); CLP + E-18 366 bpm (342–383)), whereas in-
fusion of 1 or 5 mg.kg−1.h−1 of esmolol did not induce
reduction in heart rate (CLP 419 bpm (349–472); CLP +
E-1 429 bpm (392–456); CLP + E-5 419 bpm (396–434)).
Addition of esmolol at 5 mg.kg−1.h−1 or 1 mg.kg−1.h−1
increased cardiac output (CLP 43 ml.min−1 (25–58);
CLP + E-1 86 ml.min−1 (66–97); CLP + E-5 89 ml.min−1
(66–101); CLP + E-18 60 ml.min−1 (49–80)), but
decreased hyperlactatemia (CLP 2.5 mmol.l−1 (1.6–
3.5); CLP + E-1 1.3 mmol.l−1 (0.7–1.5); CLP + E-5
1.4 mmol.l−1 (0.6–2.0); CLP + E-18 1.6 mmol.l−1 (1.2–2.4))
(Table 2).
Compared to animals in the CLP group, maximum
contractility of the thoracic aorta to Phe tended to
increase under esmolol infused at all tested doses,
although only the increase with 5 mg.kg−1.h−1 of in-
fused esmolol was statistically significant (Fig. 1a).
Maximum relaxation ability of the thoracic aorta to
Ach tended to be improved by esmolol at all doses
although it was only statistically significant at 5 and
18 mg.kg−1.h−1 (Fig. 1b).
Compared to animals in the CLP group, the max-
imum contractility of SMA to Phe also tended to
increase under esmolol at all doses. Statistical signifi-
cance was only observed under esmolol infused at 5
and 18 mg.kg−1.h−1 (Fig. 1c). Maximum relaxation
ability of SMA to Ach tended to be improved by
esmolol at all doses. Esmolol infused at 1 and
18 mg.kg−1.h−1 (Fig. 1d) had a statistically significant
effect, whereas esmolol at 5 mg.kg−1.h−1 did not dem-
onstrate significant improvement (Fig. 1d).
Effect of different doses of esmolol on circulatory
inflammatory mediators
Compared to animals in the sham group, CLP was
associated with increased plasma levels of IL-6 and
IL-10. Addition of esmolol at all tested doses in ani-
mals that underwent CLP resulted in a decrease in
plasma IL-6 (Fig. 2).
Effect of different doses of esmolol on CLP-induced
inflammatory pathways in cardiac and vascular tissues
In both the heart and thoracic aorta, CLP was associated
with a significant increase in the expression levels of
phosphorylated nuclear factor-κB (p-NF-κB), inducible
nitric oxide synthase (iNOS) and degradation of nuclear
factor of kappa light polypeptide gene enhancer in B-
cells inhibitor (IκBα) compared to animals in the sham
group, whereas phosphorylated protein kinase B (p-
AKT)/pan-AKT ratio and phosphorylated endothelial ni-
tric oxide synthase (p-eNOS)/eNOS ratio were
decreased in animals that underwent CLP compared to
the sham group (Figs. 3 and 4).
Fig. 1 Vasoreactivity evaluated by myography. Ex vivo vascular responsiveness to phenylephrine and concentration–response curves to
acetylcholine in rat thoracic aorta and mesenteric resistance arteries from sham, cecal ligation and puncture (CLP) and CLP + esmolol (CLP + E)
groups (n = 8 per group). a and c Contraction of the vessel (in mN.mm−1) as a function of increasing concentrations of phenylephrine (Phe)
expressed as log of Phe [M, mole/L]. b and d Relaxation of the vessel (in percent) as a function of increasing concentrations of acetylcholine (Ach)
expressed as log of Ach [M, mole/L]. Circles, squares and triangles represent median; upper edges of error bars represent the 75th percentile in
each group; *p < 0.05. *Sham vs. CLP, CLP vs. CLP + E-5 and CLP vs. CLP + E-18 (b). *Sham vs. CLP, CLP vs. CLP + E-1 and CLP vs. CLP + E-18 (d). E-1
esmolol 1 mg.kg−1.h−1, E-5 esmolol 5 mg.kg−1.h−1, E-18 esmolol 18 mg.kg−1.h−1. a and b aorta and c and d mesenteric arteries
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Cardiac tissue
Compared to the CLP group, the most complete anti-
inflammatory pattern was observed in the CLP + E-5
group of animals. Thus, addition of esmolol at
5 mg.kg−1.h−1 improved the p-AKT/pan-AKT ratio;
increased the p-eNOS/eNOS ratio and decreased the
expression levels of p-NF-κB and iNOS (Fig. 3).
Thoracic aorta
Changes in the thoracic aorta were similar to those
observed in cardiac tissue. Compared to CLP alone,
addition of esmolol at 5 mg.kg−1.h−1 improved the p-
AKT/pan-AKT ratio, the p-eNOS/eNOS ratio and
decreased the expression levels of p-NF-κB and
iNOS.Degradation of IκBα was not influenced by
esmolol addition at any dose in cardiac tissue or the
thoracic aorta (Fig. 4).
Adrenergic modulation after infusion of different doses of
esmolol
Septic shock was associated with downregulation of
α1-adrenoreceptor mRNA in the thoracic aorta
(Additional file 2: Figure S2 A1). There was no
change in α1-adrenoreceptor mRNA expression
induced by the addition of esmolol at any dose
(Additional file 2: Figure S2 A-2). Expression of β1-
adrenoreceptor and β2-adrenoreceptor mRNA in the
heart was unchanged by septic shock (Additional file 2:
Figure S2 B1 and C1). Likewise, addition of esmolol at any
dose did not induce any change in β1-adrenoreceptor and
β2-adrenoreceptor mRNA expression (Additional file 2:
Figure S2 B2 and C2).
Discussion
The main findings of the present study are that, in ex-
perimental septic shock, a selective β1-blocker such as
esmolol, at a dose that does not decrease heart rate, still
improved myocardial function and vasoreactivity. These
benefits were associated with downregulation of inflam-
matory pathways at both the systemic and tissue levels.
Model characteristics
All animals were resuscitated 4 hours after surgery with
adapted antibiotics and fluids in order to mimic the set-
ting usually observed at the bedside. To avoid any inter-
ference with the adrenergic system, catecholamines were
not administered in this study. In this model, all animals
that underwent CLP displayed the typical pattern of sep-
tic shock, including hypotension, low cardiac output,
hyperlactatemia and vascular hyporesponsiveness to cat-
echolamines, as in our previous study [14, 18]. More-
over, low concentrations of isoflurane were deliberately
used to minimize the impact of anesthesia on cardiac
and vascular functions [19].
Effects of esmolol in animals with septic shock
When compared to CLP, the present results demonstrate
that low doses of esmolol at 5 and 1 mg.kg−1.h−1, which
did not induce a reduction in heart rate, also displayed
beneficial effects on cardiovascular function, including
increases in cardiac output, mean arterial pressure and
vasoreactivity. While high doses of esmolol have consist-
ently been associated with non-deleterious effects on
cardiac and vascular functions in small-animal models of
sepsis, the results are more contested in large-animal
models [8, 9, 11, 13]. For example, administration of
high doses of esmolol in septic pigs has been shown to
systematically induce a significant decrease or a trend
toward a decrease in the cardiac index [20, 21].
Similarly, in humans, several teams report the efficacy
of esmolol, titrated to lower heart rate, in patients with
septic shock and tachycardia [10, 15, 16]. For example,
Fig. 2 Assessment of circulatory pro-inflammatory/anti-inflammatory
cytokine levels of IL-6 (a), and IL-10 (b) as measured by ELISA. Data are
expressed as concentration (pg.ml−1); black lines indicate medians ±
interquartile range (in color). Sham, n= 7; all other groups, n= 8. *p< 0.05.
CLP cecal ligation and puncture, E-1 esmolol 1 mg.kg−1.h−1, E-5 esmolol
5 mg.kg−1.h−1, E-18 esmolol 18 mg.kg−1.h−1
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Morelli et al., in the JAMA study, demonstrated efficient
reduction in heart rate, but also observed a decrease in
cardiac output in the first 24 hours in the esmolol group
compared to placebo, even though tissue perfusion ap-
peared to be preserved [10]. Similar to our results on
vascular reactivity, Morelli et al. also recently found that
reduction in heart rate in patients with septic shock
treated by esmolol induced an improvement in vascular
tone related to a decrease in arterial elastance [16]. In all
of these experimental or clinical studies, the reduction
in heart rate was achieved after excluding the compensa-
tory nature of tachycardia by adapted fluid resuscitation.
Finally, lower doses of esmolol may prove valuable in
hemodynamically instable patients in whom the preload
independency is difficult to achieve.
Modulation of inflammation by low doses of esmolol
Findings herein demonstrate that esmolol at low doses
still improved cardiovascular function in experimental
septic shock without any impact on heart rate, notably
through modulation of inflammatory pathways. In keep-
ing with previously published studies of esmolol, reduc-
tion in heart rate by ivabradine in an experimental
model of septic shock is not associated with a significant
decrease in cardiac output, mean arterial pressure or in-
crease in lactate level [8, 10, 11, 14, 15]. One potential
explanation is that isolated reduction in heart rate may
be associated with economized cardiac function and
maintenance of hemodynamic stability. However, in the
same experimental study, it was also found that, in con-
trast to β-blockers, isolated reduction in heart rate by
ivabradine did not induce any change in the most com-
monly assessed inflammatory pathways in rats with sep-
tic shock [14]. Thus, it could be argued that the
correction of elevated heart rate, even if crucial (particu-
larly when tachycardia is prolonged in time), is not the
only expected endpoint with the prescription of β1-
blockers during septic shock [22].
At the initial stages, patients with septic shock have an
exaggerated pro-inflammatory and anti-inflammatory
response, the severity of which is related to outcome
[23]. In experimental models of septic shock, including
the present study, addition of esmolol at all doses was
systematically associated with modulation of inflamma-
tion at both systemic and tissue levels [8, 9, 11, 13].
Similar to Ackland et al., we also observed global
Fig. 3 Western blot analysis of protein expression in the heart. Western blots revealing phosphorylated AKT (p-AKT) (a), phosphorylated
endothelial nitric oxide synthase (p-eNOS) (b), nuclear factor - κB (NF-κB) (c), nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor, alpha (IκBα) (d) and inducible nitric oxide synthase (iNOS) (e). Proteins were obtained from heart lysates (n = 8) prepared
from all experimental rat groups. A typical western blot is shown below each histogram. Densitometric analysis (n = 8) was used to calculate the
normalized protein ratio. Data are expressed as median ± interquartile range. Upper edges of error bars represent the 75th percentile in each group.
*p < 0.05. CLP cecal ligation and puncture, E-1 esmolol 1 mg.kg−1.h−1, E-5 esmolol 5 mg.kg−1.h−1, E-18 esmolol 18 mg.kg−1.h−1
Wei et al. Critical Care  (2016) 20:407 Page 7 of 10
downregulation of both anti-inflammatory and pro-
inflammatory cytokines by esmolol in our study [13].
This modulation of inflammation could also account for
the findings in the studies of Fuchs et al. and Macchia
et al., in which chronic administration of β-blockers was
associated with an improved survival rate in patients
who subsequently developed septic shock [24, 25].
Consequently, β1-blockers may act at two levels:
hemodynamically by way of reduction in heart rate, and
in an inflammatory manner through their direct anti-
inflammatory properties [26].
Modulation of adrenergic receptor mRNA expression with
esmolol
Septic shock is most often associated with downregula-
tion of vascular α1-adrenoreceptor expression [27, 28].
This downregulation is likely a consequence of a massive
NF-κB activation-induced release of pro-inflammatory
cytokines generated by sepsis [29]. In our previous study,
addition of esmolol 18 mg.kg−1.h−1 was associated with
significant improvement in the mRNA level of α1-
adrenoreceptor [11]. However, we were unable to confirm
this finding in the present study. One possible explanation
is that in order to be as accurate and reliable as possible,
three housekeeping genes were used in the present study
to normalize the results versus only one in the previous
study. Indeed, housekeeping gene expression can vary
considerably, as reported in numerous studies [30, 31].
No change in β1-adrenoreceptor and β2-adrenoreceptor
mRNA expression was observed in the heart in animals
with sepsis in the current study. Only one experimental
study has suggested that septic shock is associated with
reduction in β1-adrenoreceptor mRNA and protein levels
in heart tissue in the late phase [32]. In addition, it could
also be hypothesized that the total amount of adrenorecep-
tors produced does not significantly differ during septic
shock and consequently that mRNA quantification may
not be the appropriate measure. Indeed, adrenoreceptor
desensitization includes several other processes, including
phosphorylation, catecholamine-induced internalization
and degradation via a lysosomal pathway [33, 34]. Investi-
gating these processes may prove of interest in future
studies.
Study limitations
Despite massive fluid administration 10 ml.kg−1.h−1, we
cannot rule out the possibility that our CLP model dis-
played some degree of hypovolemia considering that in
Fig. 4 Western blot analysis of protein expression in the thoracic aorta. Western blots revealing phosphorylated AKT (p-AKT) (a), phosphorylated
endothelial nitric oxide synthase (p-eNOS) (b), nuclear factor-κB (NF-κB) (c), nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, alpha (IκBα) (d) and inducible nitric oxide synthase (iNOS) (e). Proteins were obtained from thoracic aorta lysates (n = 8) prepared from
all experimental rat groups. A typical western blot is shown below each histogram. Densitometric analysis (n = 8) was used to calculate the
normalized protein ratio. Data are expressed as median ± interquartile range. Upper edges of error bars represent the 75th percentile in each
group. *p < 0.05. CLP cecal ligation and puncture, E-1 esmolol 1 mg.kg−1.h−1, E-5 esmolol 5 mg.kg−1.h−1, E-18 esmolol 18 mg.kg−1.h−1
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animals that underwent CLP, cardiac output was mark-
edly decreased and that the ejection fraction tended to
increase. In the study of Rudiger et al., the decline in
stroke volume and left ventricular end-diastolic volume
compared to animals in the sham group was attenuated
by an additional 25 ml.kg−1 body weight of fluid boluses
of hetastarch at 6 hours and 10 ml.kg−1 at 24 hours [35].
It is likely that additional volume fluid loading in our
mode, would have been beneficial to hemodynamic re-
covery. At the bedside, such a clinical pattern should be
corrected by individually adapted fluid and vasopressor
treatment, even though fluid management remains ex-
tremely challenging in patients with septic shock [36].
Consequently, while reduction in heart rate is counterin-
tuitive in instances of hypovolemia, on the contrary, a
lower dose of esmolol may appear more appropriate in
patients with septic shock. In the present design, we
attempted a minimally invasive strategy for the assess-
ment of cardiac function by echocardiography. As a
result, we were not able to assess intrinsic myocardial
inotropism and thus, confirm the observed improvement
in the esmolol groups. Finally, it would have been of
particular interest to investigate the mortality rate in
each group in a specific survival sub-study.
Conclusion
During experimental septic shock, addition of low doses
of esmolol, which do not induce reduction in heart rate,
is associated with in vivo hemodynamic improvements
and better ex vivo vasoreactivity. These benefits appear
to be related to inflammatory modulation at both the
systemic and tissue levels. These findings, which neces-
sarily need to be confirmed, offer new insights into the
approach to prescribing esmolol during septic shock and
in the design of future clinical trials of esmolol use
during septic shock.
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